ClinicalTrials.gg
CompletedNCT04584515Updated Aug 24, 2021

IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers

A Phase 1 interventional study of IMP4297 40 mg and IMP4297 100 mg in Solid Tumor, sponsored by Impact Therapeutics, Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-24.

Sponsored by Impact Therapeutics, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A Phase I, Open-label, Fixed-Sequence Study to Evaluate the Effect of Multiple-dose Itraconazole or Rifampicin Capsules on the Single-dose PK Profiles of IMP4297 Capsules in Healthy Subjects

Read the detailed description

Study design A Phase I, single-center, open-label, fixed-sequence study is designed to evaluate the effect of multiple-dose Itraconazole or Rifampicin Capsules on the single-dose PK profiles of IMP4297 Capsules in healthy Chinese subjects.

32 subjects are planned to be enrolled (at least 12 subjects complete the study on one side).

Two parallel groups will be planned in this study with 16 subjects enrolled in each group. Two cycles are set for each group. The first group will be given IMP4297 and Itraconazole in a fixed sequence (two dosing regimens); The second group will receive IMP4297 and Rifampicin in a fixed sequence (two dosing regimens).

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Impact Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects fully understand the purpose, nature, methods and possible adverse reactions of the trial, voluntarily participate in the trial, and sign an form before any trial procedure, and promise to participate in all procedure of the trial.
  2. Healthy Chinese male subjects aged 18 to 55 (inclusive) at the time of signing informed consent form.
  3. (BMI) ranges from 19.0 to 26.0 kg/m2 (inclusive); body weight ≥ 50.0 kg.
  4. Subjects can communicate well with the investigators and understand and abide by the requirements of this trial.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with past and present diseases with clinical abnormality in the opinion of the investigator, including but not limited to disease concerning nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolic system and skeletal system;
  2. Subjects with allergic history (including drug and food allergies, etc.).
  3. Subjects with history of dysphagia or any gastrointestinal disease that affects drug absorption judged by the investigator.
  4. Subjects who have received surgery within 3 months before screening, or plan to have surgery during the trial period, or those who had surgery that will affects drug absorption (e.g. gastrectomy).
  5. Subjects who cannot tolerate venipuncture, or have a history of needlesickness and fainting at the sight of blood.
  6. Subject with lactose intolerability (who having had milk diarrhea).
  7. Subjects who have drug abuse history within 6 months before screening, or have a positive urine drug screening (screening or baseline period) result.
  8. Subjects who have used narcotics within 3 months before screening.
  9. Subjects who consumed an average of more than 14 units of alcohol per week (1 unit of alcohol = 360 mL beer, 150 mL wine, or 45 mL liquor) within 3 months before screening, or who had a positive result of alcohol breath test (screening or baseline period), or could not give up alcohol during the trial.
  10. Subjects who consumed an average of more than 5 cigarettes per day within 3 months before screening, or who could not stop using any tobacco products during the trial.
  11. Subjects who consumed an average of excessive amounts of tea, coffee and / or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months before screening.
  12. Subjects who have participated in clinical trials of other study drugs/devices within 3 months before the first dose of the drug, or have participated in 3 or more clinical trials of drugs/devices in the past year; if other study drugs have a longer half-life, the time interval will be longer and is required to be 5 half-lives of the drug.
  13. Subjects who donated blood including blood component or have massive blood loss (2,200 mL), or received blood transfusion or used blood products within 3 months before screening.
  14. Subjects who received vaccination within 4 weeks before screening.
  15. Subjects who have taken any drugs [such as: barbiturates, carbamazepine, phenytoin, , omeprazole; SSRI antidepressants, cimetidine, macrolides, nitroimidazoles, sedative hypnotics, fluoroquinolones, antihistamines, antivirals (such as saquinavir), calcium antagonists (such as diltiazem, verapamil), rifamycins (such as rifampin)] that inhibit or induce the liver to metabolize drug within 28 days before the first dose of the investigational drug. If the past drug used has a longer half-life, the time interval will be longer and is required to be 5 half-lives of the drug, eg, Phenobarbital requires a 5-week .
  16. Subjects who have taken prescription drugs, over-the-counter drugs, dietary supplements or Chinese herbal medicine within 14 days before the first dose of the investigational drug. If the past drug used has a longer half-life, the time interval will be longer and is required to be 5 half-lives of the drug.
  17. Any test result of surface antigen, virus antibody, (HIV) antibody, or treponema pallidum antibody is positive.
  18. At screening, vital signs (blood pressure, pulse and body temperature) examination, comprehensive physical examination and laboratory tests (hematology, blood biochemistry, urinalysis) indicate abnormal results with clinical significance according to the investigator. The reference normal range of vital signs (including the cut-off value) is as follows: Sitting systolic blood pressure is 90 to 139 mmHg, diastolic blood pressure is 60 to 89 mmHg, pulse is 50 to 100 bmp, body temperature (frontal temperature) is 36.0 to 37.0°C. The specific situation is comprehensively determined by the investigator.
  19. At screening after a quiet rest for at least 10 min, the interval (corrected by Fridericia's formula, QTcF = QT/RR1/3) > 450 msec or QRS complex > 120 msec was obtained by 12-lead in supine position. If QTcF is more than 450 msec or QRS is more than 120 msec, 12-lead ECG measurement should be repeated twice, and the average value of QTcF or QRS measured three times is judged by the investigator as abnormality with clinical significance.
  20. Subjects who are allergic to IMP4297, Itraconazole, Rifampicin, or to any ingredients of these preparations.
  21. Vigorous exercise cannot be avoided within 48 hours before the first dose of the investigational drug and during the trial.
  22. Subjects who consumed any food or beverages containing alcohol, caffeine, chocolate, or rich in xanthine within 48 hours before the first dose of the investigational drug; or those who cannot abstain from these products during the trial.
  23. Subjects who cannot abstain from grapefruit or grapefruit-related citrus (eg, pomelo) or juice within 7 days before the first dose of investigational drug and during the trial;
  24. Subjects or its partners who have birth plan, or are unwilling to adopt effective methods (Annex 2), or have sperm donation plan throughout the trial and within 180 days after the last dose of the investigational drug.
  25. Subjects who are unwilling or unable to follow the lifestyle guidelines described in the study protocol (such as dietary restrictions and activity requirements).
  26. Subjects who have other acute or chronic medical or psychiatric diseases, which may increase the risks of participating in this trial, or may interfere with the interpretation of the trial results, will be judged unsuitable to participate in this trial by the investigator.
  27. Subjects judged by the investigator to be unsuitable for participation in the trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    IMP4297 40 mg

    Sequential treatments of IMP4297 alone, followed by Itraconazole + IMP4297, with a washout period in between.

    Drug: IMP4297 40 mg

  • Experimental
    IMP4297 100 mg

    Sequential treatments of IMP4297 alone, followed by Rifampin + IMP4297, with a washout period in between.

    Drug: IMP4297 100 mg

Interventions

  • IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297

    Also known as: Itraconazole

  • IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297

    Also known as: Rifampin

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum concentration)

    peak concentration

    Time frame: 3 months

  2. AUC0-last (Area under the curve from time 0 to the last time with quantifiable concentration)

    AUC0-last area under the curve from time zero to the time with the last quantifiable concentration

    Time frame: 3 months

  3. AUC0-inf (Area under the curve from time 0 to infinity)

    area under the curve from time zero to infinity

    Time frame: 3 months

Secondary outcomes

  1. Number of Participants with Adverse Events That Are Related to Treatment

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

    Time frame: 3 months

  2. Tmax (Time to reach maximum concentration)

    time to reach Cmax

    Time frame: 3 months

  3. t½ (Elimination half-life)

    elimination half-life

    Time frame: 3 months

  4. CL/F (Apparent clearance)

    apparent clearance

    Time frame: 3 months

  5. Vz/F (apparent volume of distribution )

    apparent volume of distribution

    Time frame: 3 months

07

Study locations

1 site
  • Impact Therapeutics, Inc.
    Shanghai, 201210, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Mar 2021, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 14, 2020
StartActual
Nov 2, 2020
Primary completionActual
Mar 8, 2021
CompletionActual
May 27, 2021
Last update
Aug 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04584515
Lead sponsor
Impact Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Nov 2, 2020
Primary completion
Mar 8, 2021
Completion
May 27, 2021
Last update
Aug 24, 2021

Study contacts

Pingsheng Xu
principal investigator · Xiangya Hospital of Central South University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Senaparib

Start the discussion